Download PDF
Nuklearmedizin 2013; 52(04): 115-120
DOI: 10.3413/Nukmed-0563-13-02
Original article
Schattauer GmbH

Peace of mind for patients with differentiated thyroid cancer?

Seelenfriede für Patienten mit differenziertem Schilddrüsenkarzinom?
A. Vrachimis   *
1   Department of Nuclear Medicine, University Hospital Münster, Germany
,
B. Riemann   *
1   Department of Nuclear Medicine, University Hospital Münster, Germany
,
J. Gerss
2   Institute of Biostatistics and Clinical Research, University Hospital Münster, Germany
,
T. Maier
1   Department of Nuclear Medicine, University Hospital Münster, Germany
,
O. Schober
1   Department of Nuclear Medicine, University Hospital Münster, Germany
› Author Affiliations
Further Information

Publication History

received: 24 February 2013

accepted in revised form: 10 June 2013

Publication Date:
30 December 2017 (online)

    Permissions and Reprints

Summary

Differentiated thyroid carcinomas (DTC) have an excellent prognosis, with 10-year overall survival rates over 90%. In addition, DTC patients benefit from their lifelong medical surveillance. The aim of the study was to compare the patients’ overall survival with that of a matched general population. Patients and methods: We have analyzed 1497 consecutive patients with DTC, who underwent radioiodine therapy in Münster, Germany, according to international standards. We classified our patients according to the current 7th edition of the UICC (Union Internationale Contre le Cancer) classification and we compared the overall survival of the patients with the expected survival based on age and sex of the general population as provided by the Federal Statistical Office, Germany. Results: There were no significant differences in overall survival rates between DTC patients of the cohort in stages I to IVa compared to the expected survival based on age and sex of the general population. However, patients in stage IVc showed a significantly worse overall survival rate using the log-rank test (p < 0.0001). Conclusion: Patients with DTC showed excellent overall survival rates in stages I, II, III and IVa. All patients, except for those in stage IVc (M1 ≥ 45 years), had overall survival rates similar to the general population.

Zusammenfassung

Patienten mit differenziertem Schilddrüsenkarzinom haben eine exzellente Prognose mit 10-Jahres-Überlebensraten über 90%. Darüber hinaus profitieren sie von der lebenslangen medizinischen Nachsorge. Ziel der Studie war es, das Gesamtüberleben der Patienten mit derjenigen der Gesamtbevölkerung zu vergleichen. Patienten, Methode: Es wurden 1497 konsekutive Patienten mit differenziertem Schilddrüsenkarzinom untersucht, die in Münster, Deutschland, eine Radio iodtherapie nach internationalen Standards erhielten. Die Patienten wurden nach der aktuellen 7. Edition der UICC (Union Internationale Contre le Cancer)-Klassifikation eingeteilt. Das Gesamtüberleben der Patienten wurde mit der Lebenserwartung der Gesamtbevölkerung unter Berücksichtigung des Alters und Geschlechts verglichen. Hierzu wurden die Daten des Bundesamtes für Statistik, Deutschland verwandt. Ergebnisse: Es zeigten sich keine signifikanten Unterschiede zwischen den Gesamtüberlebensraten der Patienten mit differenziertem Schilddrüsenkarzinom in den Stadien I bis IVa im Vergleich zur Lebenserwartung der Gesamtbevölkerung unter Berücksichtigung des Alters und Geschlechts. Dagegen hatten Patienten im Stadium IVc eine signifikant schlechtere Gesamtüberlebensrate (p < 0,0001). Schlussfolgerung: Patienten mit differenziertem Schilddrüsenkarzinom in den Stadien I, II, III und IVa zeigten exzellente Gesamtüberlebensraten. Mit Ausnahme der Patienten im Stadium IVc (M1 ≥ 45 Jahre) wiesen alle Patienten Gesamtüberlebensraten auf, die mit der Lebenserwartung der Gesamtbevölkerung vergleichbar waren.

Keywords

Overall survival - expected survival - thyroid cancer

Schlüsselwörter

Überleben - Schilddrüsenkrebs

* Both authors contributed equally.


 

  • References

  • 1 Bhattacharyya N. A population-based analysis of survival factors in differentiated and medullary thyroid carcinoma. Otolaryngol Head Neck Surg 2003; 128: 115-23
    CrossrefPubMedGoogle Scholar
  • 2 Cooper DS, Doherty GM, Haugen BR. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214.
    CrossrefPubMedGoogle Scholar
  • 3 Dietlein M, Dressler J, Eschner W. et al. Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3). Nuklearmedizin 2007; 46: 213-219.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Eustatia-Rutten CF, Corssmit EP, Biermasz NR. et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006; 91: 313-319.
    CrossrefPubMedGoogle Scholar
  • 5 Finkelstein D, Muzikansky A, Schoenfeld D. Comparing survival of a sample to that of a standard population. J Natl Cancer Inst 2003; 95: 1434-1439.
    CrossrefPubMedGoogle Scholar
  • 6 Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
    CrossrefGoogle Scholar
  • 7 Kramer JA, Schmid KW, Dralle H. et al. Primary tumour size is a prognostic parameter in patients suffering from differentiated thyroid carcinoma with extrathyroidal growth: results of the MSDS trial. Eur J Endocrinol 2010; 163: 637-644.
    CrossrefPubMedGoogle Scholar
  • 8 Lerch H, Schober O, Kuwert T, Saur HB. Survival of differentiated thyroid carcinoma studied in 500 patients. J Clin Oncol 1997; 15: 2067-2075.
    CrossrefPubMedGoogle Scholar
  • 9 Links TP, van Tol KM, Jager PL. et al. Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis. Endocr Relat Cancer 2005; 12: 273-280.
    CrossrefPubMedGoogle Scholar
  • 10 Luster M, Clarke SE, Dietlein M. et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2008; 35: 1941-1959.
    CrossrefPubMedGoogle Scholar
  • 11 Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 418-428.
    CrossrefPubMedGoogle Scholar
  • 12 Meixner M, Hellmich M, Dietlein M. et al. Disease- free survival in papillary and follicular thyroid carcinoma. Comparison between UICC 5th and 7th classifications of T stage, and the prognostic value of primary tumour size. Nuklearmedizin 2013; 52: 71-80.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Peppercorn JM, Weeks JC, Cook EF, Joffe S. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 2004; 363: 263-270.
    CrossrefPubMedGoogle Scholar
  • 14 Podnos YD, Smith D, Wagman LD, Ellenhorn JD. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Am Surg 2005; 71: 731-734.
    Google Scholar
  • 15 Randolph GW, Duh QY, Heller KS. et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid 2012; 22: 1144-1152.
    CrossrefPubMedGoogle Scholar
  • 16 Reiners C, Hanscheid H, Luster M. et al. Radioiodine for remnant ablation and therapy of metastatic disease. Nat Rev Endocrinol 2011; 7: 589-595.
    CrossrefPubMedGoogle Scholar
  • 17 Riemann B, Schober O. MSDS study group. Are „high-risk“ patients with differentiated thyroid cancer „healthy patients“? Nuklearmedizin 2008; 47: 179-180.
    Google Scholar
  • 18 Riemann B, Uhrhan K, Dietlein M. et al. Diagnostic value and therapeutic impact of 18F-FDG-PET/CT in differentiated thyroid cancer. Results of a German multicentre study. Nuklearmedizin 2013; 52: 1-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338: 297-306.
    CrossrefPubMedGoogle Scholar
  • 20 Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumors. 7th ed. Oxford: Wiley-Blackwell; 2009
  • 21 Verburg FA, Mader U, Luster M, Reiners C. Histology does not influence prognosis in differentiated thyroid carcinoma when accounting for age, tumour diameter, invasive growth and metastases. Eur J Endocrinol 2009; 160: 619-624.
    CrossrefPubMedGoogle Scholar
  • 22 Verburg FA, Mader U, Luster M, Reiners C. Primary tumour diameter as a risk factor for advanced disease features of differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2009; 71: 291-297.
    CrossrefPubMedGoogle Scholar
  • 23 Verburg FA, Mader U, Tanase K. et al. Life expectancy is reduced in differentiated thyroid cancer patients >/= 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients. J Clin Endocrinol Metab 2013; 98: 172-180.
    CrossrefPubMedGoogle Scholar
  • 24 Verburg FA, Stokkel MP, Düren C. et al. No survival difference after successful 131I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2010; 37: 276-283.
    CrossrefPubMedGoogle Scholar
  • 25 Volante M, Collini P, Nikiforov YE. et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol 2007; 31: 1256-1264.
    CrossrefPubMedGoogle Scholar
  • 26 Vrachimis A, Schober O, Riemann B. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation. Nuklearmedizin 2012; 51: 67-72.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Woolson R. Rank tests and a one-sample Logrank test for comparing observed survival data to a standard population. Biometrics 1981; 37: 687-696.
    CrossrefGoogle Scholar